Search Results
Your search for it matches 16118 pages
Showing 1301 - 1350A Daughter of First-Generation Immigrants Follows Their Can-Do Philosophy in Her Research Efforts in Hematologic Oncology
Leukemia expert Eunice S. Wang, MD, is the daughter of first-generation immigrants, whose work ethos inspired in her a world without boundaries. “My parents were born in China during the communist era, and they immigrated to Taiwan when the communists took over in the 1940s and then subsequently...
FDA’s Crowdsourcing Initiative to Benefit Patient-Centric Clinical Trial Innovation
The U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE) recently announced a new initiative called “Project 5 in 5.” Project 5 in 5 is a crowdsourcing initiative to ultimately identify five clinically relevant questions that can be answered through use of pragmatic...
Multicultural ASCO President-Elect Was Raised in Mexico by Parents Who Instilled a Sense of Duty to Make a Difference
ASCO President-Elect Eric J. Small, MD, FASCO, developed much of his multicultural world view during his childhood in Mexico City. “My parents were expatriates who moved to Mexico in the 1950s and settled there. I was born in Mexico City and grew up bilingually. I went to an English-Spanish...
FDA Grants Accelerated Approval to Selpercatinib for Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Other Solid Tumors
On May 29, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the RET inhibitor selpercatinib (Retevmo) for pediatric patients aged 2 years and older with the following: Advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved...
Be Prepared: A Patient Perspective
I’m not prepared. It could be a few months, a few years, maybe longer. I don’t know how bad the verdict will be, but whatever it is, I’m not prepared. They always told us to be prepared. That was our motto. At age 7, I joined the Brownies, the beginning of 12 years of being molded by Girl Scout...
Are Tattoos Linked to a Heightened Risk of Lymphoma?
Tattoos may be a risk factor in the development of lymphoma, according to a recent study published by Nielsen et al in eClinicalMedicine. Background A majority of individuals receive their first tattoos at a young age, exposing them to tattoo ink for a larger portion of their lives. The long-term...
ASTRO Releases Updated Clinical Guidelines on Radiation Therapy for Patients With Bone Metastases
The American Society for Radiation Oncology (ASTRO) outlined recommendations on best practices for treating patients with symptomatic bone metastases and strategies to improve their quality of life, according to updated clinical guidelines published by Alcorn et al in Practical Radiation Oncology....
Interval Between First Colonoscopy With Negative Findings and Repeat Colonoscopy
In a Swedish cohort study reported in JAMA Oncology, Liang et al found that among individuals with no family history of colorectal cancer and a negative first screening colonoscopy, the interval to repeat colonoscopy could be extended beyond the currently recommended 10 years. Study Details The...
Can Exercise Boost the Efficacy of Rituximab in Treatment of CLL?
Sessions of moderate-to-vigorous exercise may improve the efficacy of antibody therapies, such as rituximab, used to treat chronic lymphocytic leukemia (CLL), according to a recent study published by Collier-Bain et al in Brain, Behavior, and Immunity. The findings may demonstrate the potential of...
Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally
A ground breaking staging system for de novo metastatic breast cancer has been validated in an international cohort, perhaps paving the way for more personalized care and improved outcomes for patients diagnosed with this challenging disease. The staging system, developed by surgical oncologist...
Patient Characteristics May Impact Results of AI Algorithm–Interpreted Screening Mammograms
Investigators have found that patient characteristics such as age and race may influence false-positive results from artificial intelligence (AI)-interpreted screening mammograms, according to a recent study published by Nguyen et al in Radiology. Background Although preliminary data suggested that ...
Rosai-Dorfman Disease: Sinus Histiocytosis With Massive Lymphadenopathy
“Don’t be afraid to give up the good to go for the great.” — John D. Rockefeller The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the ...
The Future of Cancer Care
The profound progress in cancer care since President Richard Nixon signed the National Cancer Act of 1971 into law is evidenced by the soaring number of cancer survivors since the law went into effect. In the 1970s, there were 3 million cancer survivors1; today, there are more than 18 million, and...
Is a Test for Early Detection of Pancreatic Cancer on the Horizon?
An investigational noninvasive exosome-based liquid biopsy shows potential for early detection of pancreatic cancer, an important unmet need, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2024.1 When combined with the biomarker CA 19-9, the...
A Look Back on an Impactful and Inspiring Presidential Year
Serving as ASCO’s 60th President over the past year has been an honor and a privilege, said Lynn M. Schuchter, MD, FASCO, who will end her Presidential term during ASCO’s Annual Meeting, being held from May 31 to June 4, 2024, in Chicago, and welcome incoming President Robin Zon, MD, FACP, FASCO,...
Applying the Power of Knowledge to Drive Positive Change in Oncology Care
An ASCO volunteer for nearly 30 years, Robin T. Zon, MD, FACP, FASCO, is humbled and honored to be elected ASCO’s 61st President, effective during the 2024 ASCO Annual Meeting, May 31 to June 4, 2024, in Chicago and online. Dr. Zon began her 4-year term in June 2023 as President-Elect and will...
We Have an IDEA: United in the Fight Against Cancer
On behalf of 2024 International Development and Education Award (IDEA) awardees, we received the decision of our acceptance in this outstanding training program offering mentorship and educational opportunities for early-career oncologists and cancer researchers with great interest. This will...
Partnering With Patients Is Integral for a Good Outcome
About 3 years ago, I woke up from a sound sleep and was having a hard time breathing. It felt like someone was sitting on my neck, constricting my airways. I could feel prominent swelling in my lymph nodes along my neck and clavicle, and I was scared. A trip to the emergency room proved fruitless, ...
Dance/Movement Therapy for Pediatric Oncology Patients and Their Caregivers
Guest Editor’s Note: Children with cancer and their caregivers face physical and psychosocial challenges during and after treatment. Dance/movement therapy has been used to improve well-being, promote healthy coping, and mitigate the impact of illness, but limited knowledge exists regarding its...
Apply Through July 31, 2024, for Survivorship Champion’s Prize
Children’s Cancer Cause, a national advocacy group in pioneering research and innovation for pediatric cancer, announced it is accepting applications for the Survivorship Champion’s Prize. This award is presented to a group, program, or institution that has demonstrated significant advancements in...
Influence of Menopausal Hormone Therapy on Gynecologic Cancer Incidence and Mortality
In 2002, the federally funded Women’s Health Initiative—a randomized, placebo-controlled clinical trial investigating the effects of menopausal hormone therapy in healthy menopausal women—was abruptly halted when it was determined that taking estrogen and progestin hormones after menopause...
Understanding the Legal and Ethical Challenges AI Poses in Oncology
The field of oncology is experiencing a revolution driven by artificial intelligence (AI) technology. Artificial intelligence tools are already being used in medical imaging analysis, treatment planning, and even patient counseling. These advancements hold immense promise for earlier cancer...
USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer
On April 30, 2024, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer.1 The USPSTF now recommends that all women undergo screening for breast cancer every other year starting at age 40 and continuing through age 74. More...
CRISPR-Edited, Off-the-Shelf CAR T-Cell Therapy Shows Proof of Concept in Renal Cell Carcinoma
Evidence from a small early trial called COBALT-RCC provides proof of concept for use of an allogeneic off-the-shelf CD70-targeted chimeric antigen receptor (CAR) T-cell therapy called CTX130 in patients with advanced clear cell renal cell carcinoma (RCC). CTX130 is engineered using gene-editing...
Study Finds the Financial Hardship Caused by Cancer Is Long-Lasting for Many Working-Age Adults
When combined with high out-of-pocket costs for cancer care, nearly 60% of working-age cancer survivors report experiencing at least one type of financial hardship, including being unable to afford medical bills, distress and worry, or delaying or forgoing needed care because of cost, according to...
NCCN Clinical Practice Guidelines in Oncology: 2024 Updates
The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...
Childhood Adiposity and Risk for Breast Cancer
Investigators have uncovered that a higher adiposity in childhood may lead to less dense tissue formation and decrease the risk of breast cancer, according to a recent study published by Vabistsevits et al in Nature Communications. Background As a result of the rising incidence of breast cancer,...
Providing Culturally Sensitive Palliative Care to Children With Cancer
In the fall of 2023, Justin Baker, MD, took on the role of Chief of the Division of Quality of Life and Pediatric Palliative Care and Director of the Quality of Life for All Program, Stanford Medicine Children’s Health, Stanford, California. He formerly worked at St. Jude Children’s Research...
Daniel M. Geynisman, MD, Named New JNCCN Editor-in-Chief
Daniel M. Geynisman, MD, has been announced as the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. Dr. Geynisman is Associate Professor in the Department of Hematology/Medical Oncology and Chief of the Division of Genitourinary Medical Oncology at Fox Chase...
AACR Cancer Disparities Progress Report 2024 Highlights Ongoing Health Inequities Experienced by Racial and Ethnic Minorities
Despite the extraordinary progress against cancer in the United States—illustrated by the continuing decline in the overall mortality rate, which fell by 33% between 1991 and 2020, and the increasing numbers of cancer survivors (over 18 million and climbing)—the burden of cancer remains...
Chemotherapy May Accelerate Physical Decline in Older Patients With Early-Stage Breast Cancer
Investigators have found that female patients aged 65 years or older with high-risk breast cancer who are treated with chemotherapy may be more likely to experience a substantial decline in physical function, according to a recent study published by Sedrak et al in the Journal of Cancer...
Appendectomy May Lower Risk of Colorectal Cancer Subtype
Appendectomy may be associated with a reduced risk of a colorectal cancer subtype positive for the tumor-promoting Fusobacterium nucleatum bacteria, according to a recent study published by Kawamura et al in the Annals of Surgery. Background Despite being historically dismissed as an unnecessary...
Survey Finds Majority of Patients With Cancer and Survivors Have or Expect to Incur Medical Debt—Even Those With Insurance
Nearly half (49%) of patients with cancer and cancer survivors report being burdened by medical debt, alongside some (13%) who report expecting to incur medical debt as part of their treatment plan, according to a new Survivor Views survey conducted by the American Cancer Society Cancer Action...
Venetoclax Plus Hypomethylating Agents: Analyzing Standard-of-Care Outcomes in Older Patients With AML
Standard-of-care treatment comprising venetoclax plus hypomethylating agents was found to be safe and effective in some patients aged 80 years and older with acute myeloid leukemia (AML), according to a recent study published by Madarang et al in Blood Neoplasia. Background Older adult patients...
A Delay in Diagnosis Led to Advanced Prostate Cancer
Cancer is not an unfamiliar disease to me. My mother died of cancer when I was 12. My oldest sister died of breast cancer, an aunt died of cancer (I don’t know which type), and my older brother is a prostate cancer survivor. So, when I was diagnosed with prostate cancer in October 2021, the news...
NIH’s New Cancer Screening Research Network and Cancer Screening Technologies
The National Institutes of Health (NIH) has launched the Cancer Screening Research Network, a clinical trials network to evaluate emerging cancer screening technologies. The new network will support the Biden-Harris Administration’s Cancer Moonshot initiative by investigating how to identify cancer ...
Pirtobrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
On December 1, 2023, pirtobrutinib (Jaypirca), a selective, noncovalent Bruton’s tyrosine kinase (BTK) inhibitor that inhibits both wild-type and C481-mutant BTK with equal low nanomolar potency and is designed to address several of the limitations of covalent BTK inhibitors, was granted...
Pembrolizumab/Chemotherapy for Advanced Biliary Tract Cancer
On October 31, 2023, pembrolizumab (Keytruda) was approved for use with gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on the double-blind KEYNOTE-966 trial...
Belzutifan in Previously Treated Advanced Renal Cell Carcinoma
On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial...
Head and Neck Cancer: Osteoradionecrosis of the Jaw Classification System
In a single-institution study reported in the Journal of Clinical Oncology, Watson et al identified risk factors for osteoradionecrosis of the jaw and developed a classification system for the condition in patients receiving radiation therapy for head and neck cancer. Study Details The study...
Bishoy Faltas, MD, Named Chief Research Officer of the Englander Institute for Precision Medicine at Weill Cornell Medicine
Olivier Elemento, PhD, Director of the Englander Institute for Precision Medicine (EIPM) at Weill Cornell Medicine, New York, recently announced that Bishoy M. Faltas, MD, has been named Chief Research Officer of EIPM effective immediately. EIPM is a large multidisciplinary institute that uses...
KEYNOTE-756 Additional Findings: Pembrolizumab Shown to Be Beneficial Regardless of Age, Menopausal Status
In updated findings from the phase III KEYNOTE-756 trial, the addition of pembrolizumab to chemotherapy in the neoadjuvant setting improved the rates of pathologic complete response for patients with high-risk estrogen receptor–positive, HER2-negative breast cancer, regardless of their age or...
DUO-E Trial: Results Support New Treatment Options in Endometrial Cancer
New research findings have highlighted the importance of personalized treatment approaches with the monoclonal antibody durvalumab based on mismatch repair (MMR) status in newly diagnosed patients with advanced or recurrent endometrial cancer, according to data presented during the Society of...
Bispecific Antibody Plus Chemotherapy Improves Survival in Patients With Gastric or Gastroesophageal Junction Cancer
Treatment with the first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab plus XELOX (capecitabine, oxaliplatin) chemotherapy demonstrated a survival advantage for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma as first-line treatment, regardless of PD-L1...
AI in Cancer Care: Embrace the Change
According to Google Chief Executive Officer Sunder Pichai, artificial intelligence (AI) is “the most profound technology humanity is working on—more profound than fire or electricity or anything that we’ve done in the past.” The impact of AI on health care and especially cancer care will not be...
ASCO Survey Finds Oncologists’ Well-Being Worsened Over the Past Decade—but Steps Can Be Taken to Mitigate Burnout
A recent survey by ASCO measuring postpandemic burnout among oncologists in the United States shows that professional satisfaction and work-life balance have significantly deteriorated over the past decade, with 59% of respondents reporting one or more symptoms of burnout, compared with 34% in...
Two Studies Support Deintensification of Treatment for HPV-Associated Oropharyngeal Cancer
Two studies presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium added support for the deintensification of radiotherapy in early-stage oropharyngeal squamous cell cancers associated with the human papillomavirus (HPV), a subtype typically more responsive to therapy compared to...
Historical Community Outreach and Engagement Efforts at NCI-Designated Cancer Centers
Investigators have examined the historical evolution of Community Outreach and Engagement initiatives at the National Cancer Institute (NCI) and NCI-designated cancer centers and provided recommendations to guide future efforts, according to a recent study published by Pohl et al in CA: A Cancer...
Newly Identified Biomarkers May Improve Diagnosis and Treatment of RCC Subtypes
Researchers have identified novel biomarkers in renal cell carcinoma subtypes, according to a new study published by Li et al in Cell Reports Medicine. The findings may help identify therapeutic targets in non–clear cell renal cell carcinomas. Background Renal cell carcinoma is a diverse cancer...
Hemihepatectomy: Outcomes With Laparoscopic vs Open Surgery
In a phase III study (ORANGE II PLUS) reported in the Journal of Clinical Oncology, Fichtinger et al found that among patients with indications for hemihepatectomy suitable for both laparoscopic and open approaches, of whom the majority had cancer, the laparoscopic approach was associated with a...
